ITSN protein family: regulation of diversity, role in signalling and pathology by Tsyba, L.O. et al.
UDC 577.21
ITSN protein family:
Regulation of diversity, role in signalling and pathology
L. O. Tsyba, M. V. Dergai, I. Ya. Skrypkina, O. V. Nikolaienko,
O. V. Dergai, S. V. Kropyvko, O. V. Novokhatska, D. Ye. Morderer,
T. A. Gryaznova, O. S. Gubar, A. V. Rynditch
Institute of Molecular Biology and Genetics, NAS of Ukraine
150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
l.o.tsyba@imbg.org.ua
Adaptor/scaffold proteins of the intersectin (ITSN) family are important components of endocytic and signalling
complexes. They coordinate trafficking events with actin cytoskeleton rearrangements and modulate the activity
of a variety of signalling pathways. In this review, we present our results as a part of recent findings on the func-
tion of ITSNs, the role of alternative splicing in the generation of ITSN1 diversity and the potential relevance of
ITSNs for neurodegenerative diseases and cancer.
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Introduction. Adaptor/scaffold proteins are important
components of many cellular processes and signalling
systems. Classical scaffolds typically do not posses any
enzymatic activity. They function as platforms for the
assembly of multiprotein complexes and can help to lo-
calize signalling molecules to a specific compartment
of the cell or/and regulate the efficiency of a signalling
pathway [1, 2].
Scaffold proteins may both facilitate or inhibit sig-
nal transduction depending on their concentration in cer-
tain compartments, regulating the strength, specificity
and duration of signal propagation.
Adaptor/scaffold proteins of intersectin (ITSN) fa-
mily are characterized by the presence of multiple do-
mains that mediate protein-protein interactions. By bin-
ding to numerous proteins, ITSNs assemble multimeric
complexes implicated in clathrin- and caveolin-media-
ted endocytosis, actin cytoskeleton rearrangements, cell
signalling and survival (reviewed in [3, 4]). Abnorma-
lities of expression of the ITSN1 gene, which is located
on chromosome 21, were associated with the endocytic
anomalies reported in patients with Down syndrome
and Alzheimer’s disease [5–7].
In this review, we present our results and summa-
rize recent findings of other laboratories concerning the
role of ITSN family members in the formation of clath-
rin-coated vesicles and regulation of signal transduc-
tion and actin cytoskeleton rearrangements. We also
describe the impact of alternative processing on the ge-
neration of diversity of the ITSN family and regulation
of the ITSN genes expression.
Role of ITSN in endocytosis and signalling. ITSN
family consists of proteins encoded by two genes, ITSN1
and ITSN2, located on human chromosomes 21 and 2,
respectively [8, 9]. ITSN1 and ITSN2 are evolutiona-
rily conserved proteins and have the same domain orga-
nization. The short isoform (ITSN-S) consists of two
Eps15 homology domains (EH1 and EH2), a coiled-
coil region (CCR) and five Src homology 3 domains
(SH3A–E). The long isoform (ITSN-L) contains an ex-
tended C-terminus consisting of a Dbl homology (DH),
a Pleckstrin homology (PH) and a C2 domain.
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The DH domain is the only catalytic domain in ITSNs.
It possesses guanine nucleotide exchange activity spe-
cific for the small GTPase Cdc42 [10]. Our data indica-
te that the DH domain of ITSN2 regulates the activity
of Cdc42 during embryo development affecting actin
cytoskeleton in Xenopus embryos. Overexpression of
the DH and PH domains in Xenopus embryos resulted
in aberrant phenotypes [11]. Embryos displayed hyper-
pigmentation and gastrulation failure that were incom-
patible with survival. The effect of expression of the con-
stitutively active Cdc42 strongly resembled that of the
DH–PH tandem. Moreover, the dominant negative Cdc42
partially rescued the developmental defects induced by
the expression of the DH–PH domains [11]. ITSN2 was
reported to regulate Cdc42 activation during epithelial
morphogenesis. Silencing of either Cdc42 or ITSN2 dis-
rupted the proper orientation of the mitotic spindle and
normal lumen formation [12]. Guanine nucleotide ex-
change activity of the brain-enriched ITSN1-L isoform
was shown to be important for dendritic spine morpho-
genesis [13, 14].
ITSN1 was shown to act at different stages of clath-
rin-mediated endocytosis (Fig. 1). It forms complexes
with a plethora of endocytic proteins including the
scaffolding adaptor Eps15 [15], large GTPase dynamin
involved in vesicle fission, a phosphoinositide phos-
phatase synaptojanin 1 [16], endocytic accessory protein
epsin [17] and others. The- and-appendage domains
of clathrin adaptor complex AP2 were shown to direct-
ly interact with the linker between the SH3A and SH3B
domains of ITSN1 [18]. Our results demonstrate the in-
teraction of ITSN1 with a membrane-deforming protein
SGIP1 and their colocalization in clathrin-coated pits
[19].
The role of ITSN1 as an important endocytic scaf-
fold has been confirmed by studies on Drosophila Dap
160 (homolog of human ITSN)-null mutants, which dis-
play severely reduced levels of dynamin, synaptojanin,
endophilin and AP180 in Dap160 mutant synapses, sug-
gesting the role of Dap160 in recruitment of endocytic
proteins to the presynaptic terminals [20, 21]. A redu-
ced number of exocytosis events in chromaffin cells and
a slowing of endocytosis in neurons were also detected
in ITSN1 null mice [22].
Initially, the role of ITSN1 in clathrin-mediated en-
docytosis was thought to be restricted to the invagi-
nation and fission stages [15]. Recently, ITSNs and
Eps15 were shown to be necessary for initiation of cla-
Fig. 1. ITSNs are important components of clathrin-mediated endocytosis and signalling. Upon ligand binding, plasma membrane signalling re-
ceptors such as receptor tyrosine kinases undergo dimerization, auto-phosphorylation and ubiquitylation. Ubiquitylated receptors are recognized
by adaptors, such as Eps15 and epsin, and recruited to clathrin-coated pits. After vesicle scission, receptors undergo sorting and are either recycled
back to the plasma membrane or directed to lysosomes for degradation
thrin-coated pit assembly. It was found that ITSNs and
Eps15 regulate clustering of membrane-sculting pro-
teins FCHo, which mark the sites of clathrin-coated pits
formation and act as clathrin-coated pit nucleators [23]
(Fig. 1).
ITSN1 is also an important component of the exocy-
tic machinery. ITSN1 interacts with SNAP-25 [16], a
protein of the SNARE complex that is critical for the do-
cking and fusion of secretory granules to the plasma
membrane. Moreover, the DH domain of ITSN1-L is im-
portant for the actin cytoskeletal rearrangements requi-
red for exocytosis in neuroendocrine cells [24]. Silen-
cing of ITSN1 strongly inhibited exocytosis and simul-
taneously prevented secretagogue-induced activation of
Cdc42. ITSN1-L has been proposed to couple Cdc42-
mediated actin remodelling involved in the late stages
of exocytosis with the recruitment of the endocytic ma-
chinery required for the subsequent compensatory endo-
cytosis in secretory cells [25].
Endocytosis is a critical component in membrane re-
ceptor signalling. Although endocytosis terminates re-
ceptor signalling [26], it also has emerged as an essential
step in the successful activation of receptor-dependent
signalling pathways [27, 28]. Very recently, it has been
shown that inhibition of early stages of clathrin-me-
diated endocytosis, by knockdown of ITSN2 or clath-
rin heavy chain, attenuated granulocyte-macrophage
colony stimulating factor receptor (GMR)-mediated sig-
nalling, whereas inhibition of the membrane constric-
tion step during clathrin-coated vesicle formation enhan-
ced GMR signalling. Moreover, an ITSN2-non-binding
mutant of GMR defective in targeting to clathrin-coa-
ted pits failed to activate JAK2 kinase [29].
Several experimental data suggest that ITSNs are
one of the key molecules that link endocytosis and sig-
nal transduction. We and other laboratories have de-
monstrated that ITSN1 through its SH3 domains forms
complexes with E3-ubiquitin ligases of Cbl family [30–
32] as well as with Sprouty 2, a negative regulator of Cbl
[33, 34] (Fig. 1). These interactions lead to enhancing
Cbl-mediated ubiquitylation and degradation of epider-
mal growth factor receptor (EGFR) [30, 33]. Moreover,
our recent results demonstrate that ITSN1 forms a stab-
le complex with scaffolding protein Ruk/CIN85 that re-
gulates recruiting the Cbl–EGFR complex to endoso-
mes for downregulation of receptor tyrosine kinase, as
well as is involved in cytoskeletal rearrangements and
apoptosis [35]. CIN85/ITSN1/Cbl-b complexes were
found to be localized in clathrin-coated pits [31].
Recently, it was shown that interaction of ITSN1
with endocytic adaptor Dab2 was important for interna-
lization of integrin 1, a specific cargo for Dab2 adap-
tors [36]. It was demonstrated that downregulation of
ITSN1 via siRNA inhibits Erk1/2-MAPK and its direct
activator MEK and leads to mitochondrial apoptosis of
cultured human lung microvascular endothelial cells [37].
Downregulation of ITSN1 expression in mouse lungs
by siRNA in vivo treatment caused endothelial cells death
and lung injury, followed by endothelial phenotypic
changes regarding hyper-proliferation and apoptosis-re-
sistance [38].
ITSN1 was also shown to regulate the survival of
neuronal cells through the activation of the PI3K–AKT
pathway by interaction with PI3K–C2. Decreasing
ITSN expression by shRNA inhibited the PI3K–C2–
AKT signalling pathway and dramatically increased
apoptosis in both neuroblastoma cells and primary corti-
cal neurons [39].
Recently, the results of yeast two-hybrid screen for
proteins that bind ITSNs were published. It was found
127 potential ITSN-binding proteins involved in the
membrane curvature, several cellular pathways inclu-
ding Rab and Arf GTPase regulation, receptor tyrosine
kinase regulation, and inositol phosphate/phosphati-
dylinositol metabolism [40]. Several nuclear proteins
including RNA binding proteins and transcription fac-
tors were found to be potential ITSN partners. Therefo-
re, additional studies are needed for complete understan-
ding ITSN-interacting network.
Alternative splicing and alternative transcription
of ITSN1. Two major ITSNs isoforms are produced by
alternative splicing of exon 30 that provides the termi-
nation codon for the short isoform. Recently, we and
others identified additional splicing events affecting
ITSNs mRNA and binding properties of the correspon-
ding protein isoforms.
Four evolutionarily conserved in-frame alternative
splicing events affecting ITSN1 mRNAs were found in
mice and humans [9, 16, 41] (Fig. 2). These events in-
clude:
(1) the use of an alternative 3'-splice site internal to
exon 6 that results in truncation of exon 6 and deletion
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of 37 amino acids between the EH1 and EH2 domains.
Approximately 3 % of ITSN1 transcripts contain a trun-
cated exon 6 [42];
(2) splicing of the neuron-specific exon 20 that en-
codes 5 amino acids in the SH3A domain. ITSN1 trans-
cripts containing exon 20 were detected only in neu-
rons. The expression of such transcripts is develop-
mentally regulated [41, 43]. The frequency of the + exon
20 variant of ITSN1 increases during fetal brain deve-
lopment whereas the level of the transcript lacking exon
20 decreases respectively;
(3) skipping of exons 25 and 26 that encode the SH3C
domain. The ratio of ITSN1 isoforms with and without
exons 25 and 26 varies in fetal and adult brain [9, 41].
In other tissues about 20 % of all ITSN1 transcripts lack
exon 25 and 26 [42];
(4) skipping of exon 35 encoding 31 amino acids of
the DH domain and 25 residues of the DH–PH interdo-
main linker. Skipping of exon 35 occurs in approxima-
tely 10 % of ITSN1-L isoforms, but the ratio of ITSN1-L
transcripts with and without exon 35 differs in brain and
other tissues.
We also found ITSN1 isoform with an alternative C-
terminus, which is encoded by exon 22a [44]. Inclusion
of exon 22a results in the generation of the shortest
ITSN1 transcript (ITSN1-22a) that encodes a protein
containing two EH domains, coiled-coil region, SH3A
domain and specific C terminal domain (CTD). ITSN1-
22a binds via its CTD to the SH3 domain of the endo-
cytic protein amphiphysin 1 and the SH3A domain of
ITSN1. We demonstrated intramolecular interaction wi-
thin ITSN1-22a that negatively regulates its associa-
tion with the ubiquitin ligase Cbl [44].
Different combinations of splicing events descri-
bed above could generate 16 variants of the ITSN1-L, 8
variants of the short ITSN1 isoforms and 4 variants of
the ITSN1-22a isoforms. We cloned all eight variants of
ITSN1-S [42].
Although the function of the most alternatively spli-
ced isoforms of ITSNs are poorly understood, the role
of alternative splicing was clearly demonstrated in case
of the ITSN1 microexon 20 splicing that provides a me-
chanism for tissue-specific control of protein–protein
interactions. Using mutational analysis, we found that
neuron-specific insertion of a microexon 20 regulates
of the SH3A domain specificity due to the shifting of ne-
gatively charged amino acids towards the interaction
interface [45].
The neuron-specific isoform of SH3A domain binds
with significantly higher affinity the endocytic proteins
dynamin 1 and synaptojanin 1, as well as the GTPase-
activating protein CdGAP, while the ubiquitously ex-
pressed isoform preferentially interacts with the signal-
ling proteins Sos1 and Cbl [43].
In our experiments we detected multiple splicing
events that cause frameshifts in ITSN1 mRNA and intro-
duce premature termination codons that lie more than 50
nucleotides upstream of an exon–exon junction [41,
42]. Such mRNAs are expected to be degraded via the
nonsense-mediated mRNA decay (NMD) pathway [46].
The relatively high abundance of mRNAs with prematu-
re termination codons suggests the participation of alter-
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Fig. 2. Schematic representation of alternative splicing events affecting human ITSN1. Asterisk indicates a stop codon
native splicing and NMD in regulation of the expres-
sion level of ITSN1.
We also detected the ITSN1 transcripts produced
from an alternative promoter of the human ITSN1 ge-
ne, which is located in intron 5. These transcripts contain
in-frame ATG codon with strong Kozak sequence and
could encode N-terminally truncated isoforms lacking
first EH domain. Such transcripts were detected in hu-
man kidney, liver, lung and brain tissues. However, the
level of their expression was significantly lower than
that of the major ITSN1 isoforms. The region located
246–190 bp upstream of exon 6 was found to be required
for alternative promoter activity [47].
Role of ITSNs in diseases. ITSN1 was shown to be
associated with the development of several pathologies
that affect the nervous system. The ITSN1 gene is map-
ped to human chromosome 21 and its expression is up-
regulated in patients with Down syndrome (DS) [5, 48,
49]. As association between endocytic abnormalities and
pathological processes of DS and early stages of Alz-
heimer’s disease was clearly stated, ITSN1 was conside-
red to be associated with these disorders [3, 7]. Recent-
ly reported transgenic mouse model, in which ITSN1-S
is specifically overexpressed in the forebrain, exhibited
specific behavioral phenotypes and sex-dependent de-
crease in locomotor activity [5].
ITSN1-S was shown to increase aggregation of mu-
tant huntingtin during Huntington’s disease through ac-
tivation of the JNK–MAPK pathway [50]. Further-
more, ITSN1 was identified as a binding partner for
DISC1 (disrupted in schizophrenia 1) suggesting a po-
tential role in psychiatric disease as well [40]. Recent-
ly, we have identified a stable tubule-only polypeptide
(STOP) as an ITSN1-binding protein using affinity
chromatography followed by MALDI-TOF mass spect-
rometry.
STOP and ITSN1 were shown to form a complex in
vivo and to co-localize partially in rat primary hippo-
campal neurons [51]. STOP is a microtubule-stabili-
zing protein that is required for several forms of synap-
tic plasticity in the hippocampus [52]. It is widely ac-
cepted that synaptic plasticity is a physiological mecha-
nism of memory and cognition that is often disrupted in
mental disorders. Elucidation of the functional signifi-
cance of ITSN1–STOP interaction in neurons is a chal-
lenge for future research.
During evolution, viruses have developed different
mechanisms for manipulation of host signalling path-
ways to establish optimal conditions for their replica-
tion and survival. Signalling and regulatory molecules
are preferentially targeted by pathogens because they
globally regulate many cellular processes [53]. Last
year we reported that latent membrane protein 2A
(LMP2A) of Epstein-Barr virus interacts with ITSN1
and regulates its phosphorylation [54]. The interaction
occurs directly via C-terminal proline-rich motifs and
can be mediated by the Shb adaptor protein. Shb inter-
acts simultaneously with the phosphorylated tyrosines
of LMP2A and the SH3 domains of ITSN1 and media-
tes indirect binding of ITSN1 to LMP2A. We have
shown that Syk kinase promotes phosphorylation of
both ITSN1 and Shb adaptors in LMP2A-expressing
cells [54].
These results indicate that LMP2A can affect a num-
ber of host cell signalling pathways by regulating the
phosphorylation of the ITSN1 and Shb adaptors.
Given the role of ITSN in the activation of mitoge-
nic pathways, its involvement in cancer development
was proposed. It was shown that siRNA-mediated down
regulation of ITSN1 induced apoptosis, inhibited
migration and invasion of glioma cells [55, 56]. Russo
and O’Bryan [57] reported that silencing of ITSN1 in
neuroblastoma cell lines reduced their anchorage in-
dependent growth and tumor formation in a xenograft
model.
However, these effects were not associated with in-
creasing of apoptosis in ITSN1-silenced neuroblasto-
ma cell lines [57].
ITSN2 was found in gene signature that predicts
disease recurrence in breast cancer patients after adju-
vant chemotherapy with cyclophosphamide, metho-
trexate and 5-fluorouracil. High expression level of
ITSN2 was associated with prolonged disease-free sur-
vival [58]. We analyzed expression of short and long
ITSN2 isoforms in breast tumors. The lowest level of
ITSN2 expression, especially ITSN2-S isoform, was
detected in estrogen/progesterone receptor-negative,
HER2/neu-positive tumors with poor prognosis and in
estrogen/progesterone receptor-positive tumors of pa-
tients with lymph node metastasis. Amount of ITSN2-
L did not differ significantly in breast tumors analyzed
[59].
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Taking together, the results of last decade have es-
tablished the role of ITSNs as scaffolding molecules
that regulate the assembly of endocytotic proteins at the
sites of endocytosis, coordinate interaction of endocy-
tic complexes with signalling molecules and regulate
Cdc42-mediated actin dynamics. Future studies may
shed new insight into the role of these scaffolds in di-
seases, especially in cancer and neurodegenerative pa-
thologies.
Still, the open question is the mechanism of regula-
tion of ITSNs functioning in different cell types, espe-
cially the role of posttranslational modifications.
Ë. Î. Öèáà, Ì. Â. Äåðãàé, ². ß. Ñêðèïê³íà, Î. Â. Í³êîëàºíêî,
Î. Â. Äåðãàé, Ñ. Â. Êðîïèâêî, Î. Â. Íîâîõàöüêà, Ä. ª. Ìîðäåðåð,
Ò. À. Ãðÿçíîâà, Î. Ñ. Ãóáàð, À. Â. Ðèíäè÷
Ðîäèíà á³ëê³â ITSN: ðåãóëÿö³ÿ ð³çíîìàí³òòÿ ³çîôîðì, ðîëü ó
ïåðåäà÷³ âíóòð³øíüîêë³òèííèõ ñèãíàë³â òà çâ’ÿçîê ç ïàòîëîã³ÿìè
Ðåçþìå
Àäàïòîðí³ á³ëêè ðîäèíè ³íòåðñåêòèí³â (ITSN) º âàæëèâèìè êîì-
ïîíåíòàìè åíäîöèòîçíèõ ³ ñèãíàëüíèõ êîìïëåêñ³â. Âîíè êîîðäè-
íóþòü âíóòð³øíüîêë³òèííèé òðàô³ê ³ ïåðåáóäîâè àêòèíîâîãî öè-
òîñêåëåòà òà ìîäóëþþòü àêòèâí³ñòü ð³çíèõ ñèãíàëüíèõ øëÿõ³â.
Â îãëÿä³ ïðåäñòàâëåíî ðåçóëüòàòè íàøèõ äîñë³äæåíü, à òàêîæ
äàí³ ³íøèõ ëàáîðàòîð³é ñòîñîâíî ôóíêö³¿ ITSN, ðîë³ àëüòåðíà-
òèâíîãî ñïëàéñèíãó ó ôîðìóâàíí³ ð³çíîìàí³òòÿ ³çîôîðì ITSN1 ³
çâ’ÿçêó ³íòåðñåêòèí³â ç íåéðîäåãåíåðàòèâíèìè õâîðîáàìè òà çëî-
ÿê³ñíèìè ïóõëèíàìè.
Êëþ÷îâ³ ñëîâà: àäàïòîðí³ á³ëêè, ðîäèíà ³íòåðñåêòèí³â, àëü-
òåðíàòèâíèé ñïëàéñèíã, åíäîöèòîç.
Ë. À. Öûáà, Í. Â. Äåðãàé, È. ß. Ñêðèïêèíà, À. Â. Íèêîëàåíêî,
À. Â. Äåðãàé, Ñ. Â. Êðîïèâêî, Î. Â. Íîâîõàöêàÿ, Ä. Å. Ìîðäåðåð,
Ò. À. Ãðÿçíîâà, Î. Ñ. Ãóáàðü, À. Â. Ðûíäè÷
Ñåìåéñòâî áåëêîâ ITSN: ðåãóëÿöèÿ ðàçíîîáðàçèÿ èçîôîðì, ðîëü
â ïåðåäà÷å âíóòðèêëåòî÷íûõ ñèãíàëîâ è ñâÿçü ñ ïàòîëîãèÿìè
Ðåçþìå
Àäàïòîðíûå áåëêè ñåìåéñòâà èíòåðñåêòèíîâ (ITSN) – âàæíûå
êîìïîíåíòû ýíäîöèòîçíûõ è ñèãíàëüíûõ êîìïëåêñîâ. Îíè êîîð-
äèíèðóþò âíóòðèêëåòî÷íûé òðàôèê è ïåðåñòðîéêè àêòèíîâîãî
öèòîñêåëåòà, à òàêæå ìîäóëèðóþò àêòèâíîñòü ðàçëè÷íûõ ñèã-
íàëüíûõ ïóòåé. Â îáçîðå ïðåäñòàâëåíû ðåçóëüòàòû íàøèõ èññëå-
äîâàíèé è äàííûå äðóãèõ ëàáîðàòîðèé îòíîñèòåëüíî ôóíêöèè
ITSN, ðîëè àëüòåðíàòèâíîãî ñïëàéñèíãà â ôîðìèðîâàíèè ðàçíî-
îáðàçèÿ èçîôîðì ITSN1 è ñâÿçè èíòåðñåêòèíîâ ñ íåéðîäåãåíåðà-
òèâíûìè çàáîëåâàíèÿìè è çëîêà÷åñòâåííûìè îïóõîëÿìè.
Êëþ÷åâûå ñëîâà: àäàïòîðíûå áåëêè, ñåìåéñòâî èíòåðñåêòè-
íîâ, àëüòåðíàòèâíûé ñïëàéñèíã, ýíäîöèòîç.
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